Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Future Oncology

• Publication date

  2016-05-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon-2016-0031PMID 27156864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours

  2013cited by this paper
• Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.

  2013cited by this paper
• Lutetium-labelled peptides for therapy of neuroendocrine tumours

  2012cited by this paper
• Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors.

  2012cited by this paper
• Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate

  2011cited by this paper
• Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?

  2011cited by this paper
• Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

  2011cited by this paper
• Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

  2010cited by this paper
• 177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy

  2010cited by this paper
• Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

  2010cited by this paper
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

  2009cited by this paper
• Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

  2008cited by this paper
• Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs

  2008cited by this paper
• One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

  2008cited by this paper
• Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

  2007cited by this paper
• Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.

  2006cited by this paper
• Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

  2005cited by this paper
• Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?

  2005cited by this paper
• Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.

  2005cited by this paper
• Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours

  2004cited by this paper
• Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

  2004cited by this paper
• Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

  2004cited by this paper
• Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.

  2003cited by this paper
• Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

  2002cited by this paper
• Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

  2002cited by this paper
• Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

  2002cited by this paper
• End-stage renal disease after treatment with 90Y-DOTATOC

  2001cited by this paper
• Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

  2001cited by this paper
• The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.

  2001cited by this paper
• Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

  2001cited by this paper
• Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?

  2000cited by this paper
• Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

  2000cited by this paper
• Yttrium-90 DOTATOC: first clinical results

  1999cited by this paper

• Efficacy and Safety of Non-Surgical Treatments for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

  2025cites this paper
• The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials

  2021cites this paper
• Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights

  2020cites this paper
• Pancreatic Neuroendocrine Neoplasms: Does Sex Matter?

  2020cites this paper
• Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)

  2020cites this paper
• OTT_A_202867 3545..3555

  2020cites this paper
• Navigating the treatment landscape in gastroenteropancreatic neuroendocrine neoplasms

  2019cites this paper
• Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.

  2018cites this paper
• Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.

  2017cites this paper
• Formulation and purification of therapeutic dose of 90Y-labeled peptides: Some interesting radiochemistry aspects.

  2017cites this paper